Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.41 |
| ▸ | DRD3 | P35462 | 4/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 3/20 | 0.37 |
| ▸ | DRD4 | P21917 | 3/20 | 0.37 |
| ▸ | DRD5 | P21918 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5483573 | 0.81 | LMNA (0.51) | DRD2DRD3NPC1RAB9ALMNA | |
| SCHEMBL4940455 | 0.76 | ALOX12 (0.53) | DRD2DRD3LMNAALDH1A1MEN1 | |
| SCHEMBL1543858 | 0.75 | CYP3A4 (0.46) | DRD2DRD3KCNH2NPC1RAB9A | |
| SCHEMBL5485301 | 0.75 | HSD11B1 (0.34) | — | |
| SCHEMBL4941967 | 0.74 | MEN1 (0.47) | LMNAALDH1A1MEN1KMT2ATP53 | |
| SCHEMBL4940240 | 0.74 | HDAC2 (0.33) | LMNAALDH1A1MEN1KMT2ATP53 | |
| SCHEMBL4939468 | 0.74 | TSHR (0.47) | NPC1RAB9ALMNAALDH1A1KMT2A | |
| SCHEMBL4941138 | 0.73 | ALOX12 (0.52) | DRD2DRD3KCNH2RAB9ALMNA | |
| SCHEMBL4946824 | 0.73 | ALOX12 (0.51) | DRD2DRD3KCNH2NPC1LMNA | |
| SCHEMBL4945505 | 0.71 | TSHR (0.46) | NPC1RAB9ALMNAALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179188-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179188-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM5, GRIK5, GRM2 | DRD2 281/4885DRD3 454/4885KCNH2 1032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.